Pharmacokinetics and safety of cefamandole in newborn infants.

Antimicrobial Agents and Chemotherapy
M M AgbayaniH E Evans

Abstract

Cefamandole, a new parenteral cephalosporin antibiotic, was administered to 23 newborn infants with pustular skin infection due to Staphylococcus aureus for an average duration of 7.5 days. All the patients improved clinically. Elevation of serum glutamic oxaloacetic transaminase and eosinophilia were observed in nine infants each transiently during treatment. There were no abnormalities of renal functions and Coombs' test results remained negative. The levels of cefamandole in serum after either intravenous or intramuscular administration were higher and the mean life was longer than those previously reported in older infants, children, and adults.

References

May 1, 1978·The Journal of Infectious Diseases·W J RodriguezR Goldenberg
May 1, 1978·The Journal of Infectious Diseases·E A SteinbergJ M Leedom
May 1, 1978·The Journal of Infectious Diseases·B R Meyers, S Z Hirschman
Dec 1, 1978·Antimicrobial Agents and Chemotherapy·C T ChangH E Evans
May 1, 1978·The Journal of Infectious Diseases·O M KorzeniowskiM A Sande
Jun 1, 1977·Antimicrobial Agents and Chemotherapy·E A SteinbergJ Wilkins
Dec 1, 1975·Antimicrobial Agents and Chemotherapy·B R MeyersS Z Hirschman
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·I W FongW M Kirby
Mar 1, 1966·Applied Microbiology·J V BennettW M Kirby
Aug 1, 1974·Antimicrobial Agents and Chemotherapy·H C Neu

❮ Previous
Next ❯

Citations

Jun 1, 1981·Australian Paediatric Journal·N BuchananM Cvejic
Jul 1, 1981·Antimicrobial Agents and Chemotherapy·M C ThirumoorthiM J Maurer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.